Pediatric Neurology News

Compared with infants born before the COVID-19 pandemic, those born during the pandemic had decreased fetal brain development, which researchers found was linked to higher levels of distress in women giving birth during the pandemic.

Prenatal exposure to topiramate, valproate and select duotherapies was associated with increased risk for autism spectrum disorder and intellectual disability, according to a study published in JAMA Neurology.

A significant increase in ICU admissions for adolescents aged 12 to 17 years with deliberate self-harm was reported in Australia during the COVID-19 pandemic, according to a study in JAMA Network Open.

Using serotonergic antidepressants during the first trimester of pregnancy did not increase the risk for neonatal seizures or epilepsy, according to data published in Neurology.

PHILADELPHIA — Diffuse axonal injury-type lesions in postoperative MRI can predict poor outcomes for children with severe traumatic brain injury, a presenter said at the American Association of Neurological Surgeons annual meeting.

DENVER — Selective impairments in regional fetal brain growth predicted adverse development among infants with congenital heart disease, according to study findings presented at the Pediatric Academic Societies Meeting.

SEATTLE — Clinicians should consider disease-modifying therapeutics when treating patients with rare pediatric disorders, according to an expert at the 2022 American Academy of Neurology annual meeting.

SEATTLE — Sarah J. Spence, MD, PhD, shared tips on differentiating pediatric neurological conditions with overlapping symptoms, at the 2022 American Academy of Neurology annual meeting.

The amygdala, which is enlarged in children aged 2 years who are diagnosed with autism spectrum disorder, appears to accelerate in growth in the first 6 to 12 months of life, researchers reported in The American Journal of Psychiatry.

The Japan Ministry of Health, Labor and Welfare has authorized Xenpozyme for the treatment of adult and pediatric patients with non-central nervous system manifestations of acid sphingomyelinase deficiency.